abstract |
The invention relates to a topical nanoparticulate spironolactone formulation comprising nanoparticles having a mean diameter, measured by photon correlation spectroscopy, in the range of from about 300nm to about 900nm. The nanoparticles are incorporated into a crystalline network system comprising a dispersion of solid crystals of polar lipids, said lipids exposing their hydrophilic side outwards and their hydrophobic side inwards towards the spironolactone nanoparticles. |